ACTRN12623000836639招募中1 期
A Phase I/IIa Trial to determine safety of EDV™ nanocells packaged with a plasmid encoding SARS-CoV-2 spike protein in the EDV and a glycolipid a-galactosyl ceramide (COVID-EDV) in non-COVID-19 Infected, immunocompromised patients.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Participants must have a primary or acquired immunocompromising condition and should be willing to comply with protocol scheduled study visits or procedures, to the best of the subject and Investigator’s knowledge.
- •Participants must have a Negative COVID-19 test (PCR or equivalent), a baseline body temperature of less than or equal to 37·5°C, an oxygen saturation of at least 92% at baseline and have general good health as established by medical history and physical examination.
- •Reproductive criteria are as follows:
- •Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for greater than or equal to 1 year and follicle-stimulating hormone (FSH) level consistent with post-menopausal status; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy).
- •Female subjects of childbearing potential must have a negative serum pregnancy test within 14 days of the first dose.
- •Female subjects must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study drug administration. Highly effective methods of birth control include sexual abstinence, hormonal birth control, or intrauterine device (women), vasectomy or a condom with spermicide (men) in combination with barrier methods.
- •Male subjects must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study drug administration.
- •All study subjects must be willing to ensure that corresponding sexual partners practice these same methods of highly effective birth control for the same duration.
排除标准
- •1. Medical history of SARS-CoV-2 infection within 3 months of Day 1.
- •2. Prior vaccination with a COVID-19 vaccine or prior participation in a COVID-19 vaccine trial or prior treatment with a SARS-CoV-2 specific monoclonal antibody or convalescent COVID-19 plasma within 3 months of Day 1.
- •3. Significant pericardial effusions, pleural effusions or ascites.
- •4. Subject is currently diagnosed with Acute Respiratory Distress Syndrome.
- •5. Subject has experienced a history of uncontrolled: coronary artery disease, with or without angina pectoris or myocardial infarction, symptomatic congestive heart failure (New York Heart Association greater than Class II), uncontrolled hypertension (systolic greater than 160 mmHg or diastolic greater than 100 mmHg), or cardiac arrhythmias requiring anti-arrhythmic therapy.
- •6. History of uncontrolled arterial or venous thrombosis. Subjects with a history of arterial or venous thrombosis are eligible if the subject is controlled via ongoing therapeutic intervention.
- •7. Current active or uncontrolled severe infection.
- •8. Received the following procedures within 28 days prior to receiving their first dose (Day 1), (or has not recovered from the toxic effects of such therapy) including: major surgery.
- •9. QTc interval prolonging medicines should be reviewed and where possible their use should be minimized and alternate medicines that are not QTc interval prolonging considered as substitutes.
- •10. Any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
- •11. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
- •12. Platelet disorder or other bleeding disorder that may cause contraindication to injection. 13. Prior administration of other investigational agents less than or equal to 28 days prior to study Day 1.
- •14. Prior administration of attenuated vaccine in last 30 days prior to first dose.
- •15. Prior administration of inactivated vaccine in last 14 days prior to first dose.
研究者
相似试验
招募中
2 期
A study to test an oral combination of letrozole and everolimus for patients with advanced lung cancer who have progressed on first line chemotherapy.on Small Cell lung cancerNon Small Cell lung cancerCancer - Lung - Non small cellACTRN12607000218493Dept of Medical Oncology, Royal Adelaide Hospital20
已完成
不适用
A pilot study to evaluate safety and efficacy of electrohydraulic lithotripsy for difficult biliary and pancreatic stonesBiliary and pancreatic stonesJPRN-UMIN000013130Graduate School of Medicine, The University of Tokyo30
已完成
1 期
Evaluation of efficacy and safety of Ebola vaccine iEvac-Z in humaJPRN-jRCTs031190118Koga Michiko30
招募中
1 期
Phase I study for the efficacy and the safety of the perioperative urinastatin therapy in chest surgical patients with interstitial pneumonia.interstitial pneumonia, lung cancer, metastatic lung tumor, pneumothoraxJPRN-UMIN000003295Tokyo Women's Medical University of Medicine, Department of Surgery I30
已完成
1 期
Panobinostat with 5-azacytidine in patients with untreated high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML).ACTRN12610000924055The Alfred Hospital40